local_hospital

Hospital Universitario San Juan De Alicante

Address
lock Available on a paid plan

Oncology and Breast Cancer Research

At Hospital Universitario San Juan De Alicante, a major share of the clinical research portfolio focuses on Neoplasms, especially breast cancer. Trials are exploring new treatment options for early, advanced, HER2-positive, HER2-low, and hormone receptor-positive disease, with the aim of improving survival, delaying progression, and refining treatment choices for patients with difficult-to-treat cancers.

  • Advanced triple negative breast cancer and early breast cancer
  • HER2-positive, HER2-low, and HR-positive / HER2-negative breast cancer
  • Brain metastases and metastatic breast cancer
  • Testing newer targeted and immunotherapy-based approaches

This work reflects a strong interest in evaluating therapies that may be more effective than current standard options for breast cancer.

Allergology and Respiratory Disease Studies

The site’s Allergology department is actively involved in research on immune system diseases and respiratory tract diseases, with a clear focus on allergic rhinitis, rhinoconjunctivitis, and asthma. These studies are designed to assess allergen immunotherapy and other treatments that may better control symptoms and improve day-to-day quality of life.

  • Allergic rhinoconjunctivitis with or without controlled asthma
  • Moderate-to-severe allergic rhinitis and pollen-related symptoms
  • House dust mite and grass allergy treatment
  • Evaluating symptom relief and improved allergy control

Research at this hospital is helping advance more personalized care for people living with persistent allergy-related conditions.

Cardiovascular and Metabolic Medicine

Another important area of research covers cardiovascular diseases and nutritional and metabolic diseases. Trials at the site are studying conditions such as myocardial infarction, spontaneous coronary artery dissection, familial hypercholesterolemia, and type 2 diabetes, with the goal of improving prevention, recovery, and long-term disease control.

  • Heart attack and coronary artery complications
  • High cholesterol in children and inherited lipid disorders
  • Diabetes management in patients with renal impairment
  • Assessing better prevention and treatment strategies

These studies support more effective care for patients with chronic cardiometabolic conditions and acute cardiovascular events.

Hematology, Rheumatology, and Immune-Mediated Conditions

The research portfolio also includes hemic and lymphatic diseases and complex immune-related disorders. At Hospital Universitario San Juan De Alicante, trials are investigating haemophilia A and chronic inflammatory rheumatic diseases, while also looking at ways to reduce cardiovascular risk in people with inflammatory conditions.

  • Haemophilia A with factor VIII inhibitors
  • Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and lupus
  • Cardiovascular prevention in inflammatory disease
  • Improving bleeding control and long-term risk management

The overall aim is to test better approaches for managing both disease activity and related complications in these patients.

Critical Care and Serious Infection Research

The site is also involved in studies on pathological conditions, signs and symptoms such as septic shock. This research is focused on improving emergency and intensive care treatment, with the goal of supporting survival and reducing the need for prolonged organ support in severely ill patients.

  • Septic shock and early resuscitation care
  • Testing tailored treatment strategies in critical illness
  • Improving short-term outcomes in intensive care
  • Evaluating more effective supportive care approaches

These trials contribute to better decision-making in critical care medicine for patients with life-threatening infection-related complications.

Translational and Diagnostic Research

Beyond disease-specific treatment studies, the site participates in research on analytical, diagnostic and therapeutic techniques and equipment as well as broader physiological processes. This includes efforts to improve how patients are identified, monitored, and matched to the most appropriate therapy across several specialties.

  • Using diagnostic tools to refine cardiovascular risk assessment
  • Monitoring treatment response in diabetes and allergy care
  • Supporting more precise patient selection for therapy
  • Strengthening evidence for everyday clinical decision-making

The research environment at this Spanish hospital combines treatment-focused trials with studies that aim to improve diagnosis and patient stratification.

Site Overview

assignment
21
connected trials
corporate_fare
18
sponsors
science
60
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
21
Total trials linked
Highly Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 7 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 53 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
8
Sponsors (total)
18
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
21
Outperforms 81% of sites
public
Therapeutic diversity
8areas
Outperforms 82% of sites
groups
Sponsor diversity
18sponsors
Outperforms 82% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hospital Universitario San Juan De Alicante

lock Showing 1 of 21 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Capillary Refill Time-Targeted Resuscitation in Early Septic Shock Using Sodium Chloride and Lactated Ringer's Solution: A Hemodynamic Phenotype-Based StudyPontificia Universidad Catolica de ChilePhase IIINot RecruitingMay 2022Jul 2025

IMP list

lock Showing 1 of 60 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Trastuzumab Deruxtecan4Unknown2021-04-192025-06-30

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.